ExpreS2ion has filed a protocol amendment to evaluate its HER2-targeting breast cancer vaccine ES2B-C001 in combination with antibody-drug conjugates like Enhertu, potentially enhancing its commercial value.
ExpreS2ion Biotech secured crucial approval for Phase I clinical trial of ES2B-C001, their novel HER2-expressing breast cancer therapeutic vaccine, marking their entry into clinical development.
ExpreS2ion Biotechnologies receives approval to begin a Phase I clinical trial for ES2B-C001, a therapeutic vaccine targeting HER2-expressing breast cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.